IXICO today announces two further milestones in its growing Parkinson’s disease franchise. IXICO has joined seven global pharmaceutical companies including: AbbVie, AstraZeneca, Biogen, Eli Lilly and Company, Merck Sharp & Dohme, Pfizer, and UCB in the ground breaking Critical Path for Parkinson’s Consortium (CPP). Formed by Parkinson’s UK and the Critical Path Institute, CPP has a common goal of establishing best practices and more efficient protocols for clinical trial planning. Data from previous Parkinson’s trials will be collected, standardized and integrated to inform new approaches to designing clinical trials focused on early-stage Parkinson’s disease. CPP brings together researchers, drug companies and regulators with the aim to accelerate the development of safe and effective therapies for Parkinson’s disease.
Furthermore, IXICO has been awarded a contract by Oxford BioMedica to support the use of novel brain scanning in a clinical trial of a novel experimental drug for Parkinson’s disease, OXB-102. This study is expected to start in mid-2016 and is a phase I/II study to evaluate the safety and tolerability of OXB-102 and establish the optimal dose in the study patient population. IXICO will be involved for up to 5 years including long-term follow up and will apply its PET imaging expertise, image data handling and analysis technology to oversee the manufacture and use of novel radiopharmaceutical ligands, at specialist imaging centres in Europe.